GlaxoSmithKline plc (GSK) will provide updates on emerging areas of research and data from across its comprehensive respiratory portfolio of approved medicines, investigational programmes and scientific collaborations at the American Thoracic Society (ATS) conference 13-18 May, San Francisco, US, with more than 50 abstracts featured at the meeting. Data highlights will include new analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial with Breo Ellipta (fluticasone furoate/vilanterol or FF/VI 100/25mcg). Data from GSK’s dual bronchodilator treatment Anoro Ellipta (umeclidinium/vilanterol, UMEC/VI) and its anti-IL 5 monoclonal antibody Nucala (mepolizumab) will also be presented, as well as results from studies of GSK’s Ellipta inhaler.

Professor Neil Barnes, Global Franchise Medical Head, Respiratory said: “ATS is an important scientific meeting for the respiratory community, which allows clinicians, patient groups and the pharmaceutical industry to share information and developments across the spectrum of respiratory diseases. We are committed to undertaking studies and sharing data at congresses such as ATS, which help advance knowledge about respiratory disease, communicate emerging data to physicians and contribute to the debate on how to improve management of asthma and COPD.”

Amongst the abstracts being presented are data from three separate analyses of the Study to Understand Mortality and MorbidITy (SUMMIT) trial. Headline data from the trial was announced in September 2015. The study was designed to evaluate the effect of FF/VI 100/25mcg once-daily on all-cause mortality compared with placebo in patients with chronic obstructive pulmonary disease (COPD) and moderate airflow limitation who have, or are at high risk for, cardiovascular disease (CVD). These abstracts investigate the efficacy and safety data of FF/VI 100/25mcg compared to placebo. Endpoints of the analyses to be presented include efficacy outcomes; rate of lung function decline and measures of exacerbations, as well as pneumonia events.

Other key data being presented include results from study (DB2116960), investigating the efficacy and safety of UMEC/VI in patients with moderate COPD who continued to have symptoms while on tiotropium monotherapy. The study was a 12-week, multicentre, randomised, blinded* study where a total of 494 patients were randomised and received either UMEC/VI 62.5/25mcg once daily or tiotropium 18mcg once-daily.

Data informing on the prevalence of the mepolizumab target population in the real world (US and global) is being presented in two abstracts describing findings from the IDEAL study. The IDEAL study was a cross-sectional, non-drug interventional study, which assessed the eligibility of severe asthma patients for treatment with biologics. With the emergence of different biomarkers that help guide the use of biologic therapies in severe asthma, the study helps aid the understanding of the relationship between eosinophils and IgE as biomarkers in this population. It also assesses the level of unmet need in patients who may be eligible for biologic treatments.